However, because metronidazole metabolites may accumulate in patients with end-stage renal disease, these patients should be monitored for metronidazole - associated adverse effects such as central nervous system effects, including headaches, convulsions, and peripheral neuropathy (mainly numbness or paresthesias in an extremity).